-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $102

Benzinga·07/10/2025 20:41:15
Listen to the news
Leerink Partners analyst Faisal Khurshid maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $88 to $102.